Updated just now · Live
Stock analysis, price data, and AI-powered insights for Oculis Holding AG (OCS).
Oculis Holding AG operates in the Pharmaceuticals sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for OCS.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). OCS Stock Intelligence Report. [stoxpulse.com/stocks/ocs]
Disclaimer: The information on this page about Oculis Holding AG (OCS) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Oculis Holding AG.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
HC Wainwright & Co. Reiterates Buy on Oculis Holdi...
1d ago
Oculis Holding AG Announces Completion of Last Pat...
1d ago
StoxPulse AI results for OCS: Pulse Score 51.5/100. Primary sentiment trends from 4 news sources and 0 SEC filings indicate a bullish outlook.
Market Cap
$1.64B
P/E Ratio
—
EPS
—
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $44 Price Target
Oculis Holding AG Announces Completion of Last Patient Visit in Phase 3 Diamond Program with OCS-01 Eye Drops for Treatment of Diabetic Macular Edema
Oculis Completes Final Patient Visits In Both Phase 3 DIAMOND Trials For OCS-01 Diabetic Macular Edema Eye Drop Treatment
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema